Literature DB >> 18320710

Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.

Michael J Bloch1, Jan Basile.   

Abstract

Entities:  

Year:  2008        PMID： 18320710      PMCID： PMC8110166          DOI： 10.1111/j.1751-7176.2008.07917.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  2 in total

1.  Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma.

Authors:  Sergio Fazio; MacRae F Linton
Journal:  J Clin Endocrinol Metab       Date:  2009-04       Impact factor: 5.958

2.  Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.

Authors:  Ramachandran S Vasan; Michael J Pencina; Sander J Robins; Justin P Zachariah; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.